Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€15.09

€15.09

5.490%
0.78
5.490%
-

-

 
03.05.24 / Tradegate WKN: A2JLT3 / Name: Vitrolife / Stock / Healthcare Equipment & Supplies / Small Cap /
Latest predictions
02.11.23
19.38%
buy
03.06.23
-21.73%
buy
20.05.23
-28.71%
buy
Your prediction

Vitrolife AB Stock

A very strong showing by Vitrolife AB today, with an increase of €0.78 (5.490%) compared to yesterday's price.

Pros and Cons of Vitrolife AB in the next few years

Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Vitrolife AB vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Vitrolife AB 5.490% 8.095% -8.379% -25.371% -14.938% - -
Ekso Bionics Holdings Inc. -1.680% 13.488% -10.294% -10.688% -25.881% -74.477% -
Halyard Health 0.570% 6.061% -2.235% -32.171% -13.366% -50.843% -55.145%
Asensus Surgical Inc. 0.350% -3.510% -13.772% -60.800% -26.340% -86.162% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-25

Vitrolife, a key player in the healthcare equipment and supplies industry, presents financials that initially denote stability and growth potential when observed through various financial statements and ratios. The robustness of their balance sheets over the recent years suggests that the company has been maintaining a sound asset base with consistent growth in stockholder equity. However, a closer and more detailed investigation into their financials is necessary to uncover the intricacies of their performance and potential areas of concern.

Revenue and Profitability Growth: The company's total revenue reveals a positive trend, showing an upward trajectory in recent years. A noticeable aspect is the year-over-year (YOY) quarterly revenue growth which stands at 6.3%. Furthermore, the gross profit TTM (Trailing Twelve Months) is quite substantial at $1.78 billion, underscoring the company's ability to manage its cost of sales effectively and maintain profitable operations.

Solid Asset Base: The balance sheets for the years 2020-2022 reveal a consistently increasing total asset figure, which is a mark of the company's growth and ability to generate value from its assets. The total stockholder equity has also seen significant increment—a signal that the intrinsic value of the company is on the rise.

Comments

Buy Vitrolife AB
Show more

Buy Vitrolife AB
Show more